Loading...
Loading...
On Wednesday, Goldman Sachs upgraded shares of Teva Pharmaceutical Industries
TEVA from Sell to Neutral and raised the price target from $40 to $52.
Analyst Jami Rubin expects the “narrative around TEVA to change from concerns around a declining Copaxone franchise to growth and optionality in the underlying business.”
Rubin went on to propose changes management could make such as:
- Cut costs
- Narrow R&D focus
- Divest parts of business
The analyst said mergers & acquisitions are “one of the key drivers of sector performance” and believes Teva could “put about $10bn towards deal activity.”
Shares of Teva are up 1.3 percent to $50.57 in Wednesday's trading and up 26 percent year to date.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in